PROMISE
Eptinezumab Eptinezumab (ALD403) is a CGRP antagonist for the prophylaxis of frequent episodic migraines. Status: Completed FDA Approved
Eptinezumab Eptinezumab (ALD403) is a CGRP antagonist for the prophylaxis of frequent episodic migraines. Status: Completed FDA Approved
Emgality Emgality (galcanezumab) is a preventive treatment for migraines. Status: Completed FDA Approved
Aducanumab Aducanumab is an anti-amyloid beta antibody made for patients with Alzheimer’s Disease. Status: Completed FDA Approved